SillaJen Inc
KOSDAQ:215600
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
SillaJen Inc
Depreciation & Amortization
SillaJen Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SillaJen Inc
KOSDAQ:215600
|
Depreciation & Amortization
-₩874.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Depreciation & Amortization
-₩70.8B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
-22%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Depreciation & Amortization
-₩16.4B
|
CAGR 3-Years
-62%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Depreciation & Amortization
-₩2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Depreciation & Amortization
-₩3.6B
|
CAGR 3-Years
-80%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
-62%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Depreciation & Amortization
-₩3.4B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
SillaJen Inc
Glance View
SillaJen, Inc. develops oncolytic immunotherapeutics virus. The company is headquartered in Seoul, Seoul. The company went IPO on 2016-12-06. The Company’s major product is Pexa-Vec, which is in a global Phase 3 clinical trial that is used for the treatment of liver cancer. Additionally, it also offers oncolytic virus immunotherapeutics, including SJ-102, SJ-103, SJ-815, JX-929, JX-930, JX-963, JX-970 and others.970 and others.
See Also
What is SillaJen Inc's Depreciation & Amortization?
Depreciation & Amortization
-874.4m
KRW
Based on the financial report for Sep 30, 2025, SillaJen Inc's Depreciation & Amortization amounts to -874.4m KRW.
What is SillaJen Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
13%
Over the last year, the Depreciation & Amortization growth was 53%. The average annual Depreciation & Amortization growth rates for SillaJen Inc have been 11% over the past three years , 13% over the past five years .
